TITLE:
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure

CONDITION:
Prostatic Neoplasms

INTERVENTION:
Atrasentan

SUMMARY:

      The purpose of this phase II, randomized, double-blind placebo controlled, multi-center
      study is to evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects
      as measured by rate of rise in the PSA (primary objective).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Male
Age: 19 Years to N/A
Criteria:

        Inclusion Criteria:

          -  prostate adenocarcinoma,

          -  radical prostatectomy,

          -  PSA between 0.4 and 5 ng/mL,

          -  PSADT < 1 year

        Exclusion Criteria:

          -  previous hormonal therapy,

          -  salvage therapy to the pelvis within 3 months prior to randomization
      
